These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16979993)

  • 21. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
    Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
    Legendre C; Cohen D; Zeier M; Rostaing L; Budde K
    Transplant Proc; 2007 Jun; 39(5):1386-91. PubMed ID: 17580145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
    Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network database.
    Irish W; Arcona S; Gifford RJ; Baillie GM; Cooper M
    Transplantation; 2010 Jul; 90(1):23-30. PubMed ID: 20445488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
    Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
    Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.
    Salvadori M;
    Transplant Proc; 2005 Mar; 37(2):909-11. PubMed ID: 15848572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China.
    Wang Z; He JJ; Liu XY; Lin B; Zhang L; Geng L; Zheng S
    Immunopharmacol Immunotoxicol; 2015; 37(6):508-12. PubMed ID: 26525836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
    Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Report of the experience with enteric-coated sodium mycophenolate in a de novo population of kidney transplant recipients at high risk for delayed graft function.
    Novoa P; Rodríguez L; Gutiérrez L
    Transplant Proc; 2007 Apr; 39(3):600-1. PubMed ID: 17445554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.
    Salvadori M; Holzer H; de Mattos A; Sollinger H; Arns W; Oppenheimer F; Maca J; Hall M;
    Am J Transplant; 2004 Feb; 4(2):231-6. PubMed ID: 14974944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
    Martinez-Mier G; Salazar-Ramirez A
    Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
    Calvo N; Sanchez-Fructuoso AI; Conesa J; Moreno A; Barrientos A
    Transplant Proc; 2006 Oct; 38(8):2396-7. PubMed ID: 17097945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2005 Jun; 37(5):2066-8. PubMed ID: 15964340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
    Nart A; Sipahi S; Aykas A; Uslu A; Hoşcoşkun C; Toz H
    Transplant Proc; 2008; 40(1):189-92. PubMed ID: 18261583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Hardinger KL; Hebbar S; Bloomer T; Murillo D
    Clin Transplant; 2008; 22(5):555-61. PubMed ID: 18394000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
    Laftavi MR; Hai F; Laftavi H; Feng L; Said M; Patel S; Kohli R; Alnimri M; Dayton M; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):478-81. PubMed ID: 21440738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.